Literature DB >> 29339382

In Vitro Susceptibility of Neisseria gonorrhoeae Strains to Mupirocin, an Antibiotic Reformulated for Parenteral Administration in Nanoliposomes.

Ahuva Cern1, Kristie L Connolly2, Ann E Jerse2, Yechezkel Barenholz3.   

Abstract

Neisseria gonorrhoeae is an urgent antibiotic-resistant threat. This study determined the MICs of mupirocin to be 0.0039 to 0.0625 μg/ml for 94 N. gonorrhoeae strains. Cross-resistance with other antibiotics was not detected. Mupirocin, which is currently limited to topical administration, demonstrated activity by injection when delivered in nanoliposomes. The nanoliposomal formulation of mupirocin is a potential treatment for drug-resistant N. gonorrhoeae.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Nano-mupirocin; antibiotic resistance; antimicrobial activity; antimicrobial resistance; cross-resistance; liposomes

Mesh：

Substances：

Year:  2018        PMID： 29339382      PMCID： PMC5913977          DOI： 10.1128/AAC.02377-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

Review 1.  The clinical development of mupirocin.

Authors:  K A Pappa
Journal:  J Am Acad Dermatol       Date:  1990-05       Impact factor: 11.527

2.  Interaction of pseudomonic acid A with Escherichia coli B isoleucyl-tRNA synthetase.

Authors:  J Hughes; G Mellows
Journal:  Biochem J       Date:  1980-10-01       Impact factor: 3.857

3.  Effect of solubilizing agents on mupirocin loading into and release from PEGylated nanoliposomes.

Authors:  Ahuva Cern; Einat Nativ-Roth; Amiram Goldblum; Yechezkel Barenholz
Journal:  J Pharm Sci       Date:  2014-06-04       Impact factor: 3.534

4.  Ceftriaxone-resistant Neisseria gonorrhoeae, Japan.

Authors:  Makoto Ohnishi; Takeshi Saika; Shinji Hoshina; Kazuhiro Iwasaku; Shu-ichi Nakayama; Haruo Watanabe; Jo Kitawaki
Journal:  Emerg Infect Dis       Date:  2011-01       Impact factor: 6.883

5.  Gonococcal pilin variants in experimental gonorrhea.

Authors:  J Swanson; K Robbins; O Barrera; D Corwin; J Boslego; J Ciak; M Blake; J M Koomey
Journal:  J Exp Med       Date:  1987-05-01       Impact factor: 14.307

6.  Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance and a call for international collaborative action.

Authors:  Teodora Wi; Monica M Lahra; Francis Ndowa; Manju Bala; Jo-Anne R Dillon; Pilar Ramon-Pardo; Sergey R Eremin; Gail Bolan; Magnus Unemo
Journal:  PLoS Med       Date:  2017-07-07       Impact factor: 11.069

Review 7.  Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting.

Authors:  Lori Newman; Jane Rowley; Stephen Vander Hoorn; Nalinka Saman Wijesooriya; Magnus Unemo; Nicola Low; Gretchen Stevens; Sami Gottlieb; James Kiarie; Marleen Temmerman
Journal:  PLoS One       Date:  2015-12-08       Impact factor: 3.240
  7 in total
  4 in total

Review 1.  Nanobiosystems for Antimicrobial Drug-Resistant Infections.

Authors:  Foteini Gkartziou; Nikolaos Giormezis; Iris Spiliopoulou; Sophia G Antimisiaris
Journal:  Nanomaterials (Basel)       Date:  2021-04-22       Impact factor: 5.076

Review 2.  Prospects of Nanostructure Materials and Their Composites as Antimicrobial Agents.

Authors:  Anupriya Baranwal; Ananya Srivastava; Pradeep Kumar; Vivek K Bajpai; Pawan K Maurya; Pranjal Chandra
Journal:  Front Microbiol       Date:  2018-03-09       Impact factor: 5.640

Review 3.  Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions.

Authors:  Eric Y Lin; Paul C Adamson; Jeffrey D Klausner
Journal:  Drugs       Date:  2021-06-07       Impact factor: 9.546

4.  Therapeutic Potential of Injectable Nano-Mupirocin Liposomes for Infections Involving Multidrug-Resistant Bacteria.

Authors:  Ahuva Cern; Yaelle Bavli; Atara Hod; Daniel Zilbersheid; Shazad Mushtaq; Ayelet Michael-Gayego; Dinorah Barasch; Yael Feinstein Rotkopf; Allon E Moses; David M Livermore; Yechezkel Barenholz
Journal:  Pharmaceutics       Date:  2021-12-17       Impact factor: 6.321
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.